EMA Authorised: Onpattro (patisiran sodium) — Alnylam Netherlands B.V.

View source ↗

Summary

EMA has authorized Onpattro (patisiran sodium) for familial amyloidosis, with orphan designation and accelerated assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Amyloidosis

Drugs mentioned

• Onpattro (patisiran)

Snippet

Status: Authorised. Therapeutic area: Amyloidosis, Familial. MAH: Alnylam Netherlands B.V.. Decision date: 07/07/2026. Orphan medicine. Accelerated assessment